ライフサイエンスコーパス: cyclosporine A

1 20-30% by calcineurin inhibitors (FK506 and cyclosporine A).

2 nd is inhibited by the cyclophilin inhibitor cyclosporine A.

3 trast to the HBV inhibitors, telbivudine and cyclosporine A.

4 unosuppression with mycophenolate mofetil or cyclosporine A.

5 and therapy with the immunosuppressive agent cyclosporine A.

6 n infection was conducted in the presence of cyclosporine A.

7 ynthesis of the important cyclic polypeptide cyclosporine A.

8 me inhibitor Velcade or an immunosuppressant cyclosporine A.

9 disparity, followed by 12 days of high-dose cyclosporine A.

10 All animals were maintained on oral cyclosporine A.

11 iature swine treated with a 12-day course of cyclosporine A.

12 adation induced by the calcineurin inhibitor cyclosporine A.

13 as receptors for the immunosuppressive drug, cyclosporine A.

14 decreased sensitivity to the Rgg2 antagonist cyclosporine A.

15 vitro at a concentration 10 times lower than cyclosporine A.

16 imilar concentration as pharmaceutical grade cyclosporine A.

17 able and orally bioavailable natural product cyclosporine A.

18 s a target of the natural products FK506 and Cyclosporine A.

19 e cellular receptor of the immunosuppressant cyclosporine A.

20 e trough level (C0) and used higher doses of cyclosporine A.

21 transplantation (HCT) and a 45-day course of cyclosporine A.

22 e trough level (C0) and used higher doses of cyclosporine A.

23 tion of the Itpr2 promoter was attenuated by cyclosporine-A.

24 ts were randomized to receive an IV bolus of cyclosporine A (10 mg/kg) or normal saline (placebo, con

25 xic T-lymphocyte antigen-4 immunoglobulin or cyclosporine A (15 mg/kg), graft survival was significan

26 randomized to receive intravenous boluses of cyclosporine A (2.5, 10, or 25 mg/kg) or normal saline (

27 haride (3.0 mg/kg, intravenously; n = 8), or cyclosporine A (6.0 mg/kg, intravenously; n = 6) or tacr

28 FK506 (50 ng/mL) and cyclosporine A (800 ng/mL) had comparable effects.

29 Moreover, cyclosporine A, a blocker of mPTP opening, attenuates is

30 f inflammation in peripheral tissues, and by cyclosporine A, a CyPA inhibitor.

31 neuronal co-cultures through the addition of cyclosporine A, a potent immune-modulator.

32 loyed to determine whether pretreatment with cyclosporine A, a potent inhibitor of the mitochondrial

33 ubating cells with the cyclophilin inhibitor cyclosporine A, a treatment that triggered efficient ER

34 l other grafts were accepted with 12 days of cyclosporine A across both MHC-matched and MHC class I b

35 We show that cyclosporine A added to a sample containing NS5B(Delta21

36 gher in recipients aged >44 years and taking cyclosporine A (adjusted hazard ratio = 1.44; P = 0.011)

37 orine A (TCD arm; n=201) or methotrexate and cyclosporine A after transplantation of T-replete marrow

38 Cell death was partially blocked by cyclosporine A [an inhibitor of the mitochondrial permea

39 Cyclosporine A, an inhibitor of mitochondria permeabilit

40 ing justification for a clinical trial using cyclosporine A, an inhibitor of PTP opening.

41 ) or cyclophilin (using nonimmunosuppressive cyclosporine A analog) reduced tissue neutrophilia by up

42 eceptor antagonists, calpain inhibitors, and cyclosporine A analogues.

43 clobetasol, or in combination with systemic cyclosporine A and anti-alphabeta-T-cell receptor antibo

44 ium opens the channel, which is inhibited by cyclosporine A and ATP/ADP.

45 on of immune tolerance--via oral delivery of cyclosporine A and azathioprine for two months at the ti

46 Experiments using cyclosporine A and cardiac-specific CaMKIIdelta knockout

47 In addition to rescue by cyclosporine A and collagen VI, this cellular phenotype

48 ath and ROS production were also reversed by cyclosporine A and diazoxide, chemicals that regulate th

49 Calcineurin inhibitors such as cyclosporine A and FK506 are effective immunosuppressant

50 ibitors of calcineurin/NFAT binding, such as cyclosporine A and FK506, are broadly used in organ tran

51 ited by both calcineurin-specific inhibitors cyclosporine A and FK506.

52 A-matched related donor and prophylaxis with cyclosporine A and methotrexate were associated with low

53 noclonal antibodies, total body irradiation, cyclosporine A and mycophenolate mofetil (12 doses), and

54 Cyclosporine A and nonimmunosuppressive cyclophilin (Cyp

55 overy of powerful immunotherapeutics such as cyclosporine A and rapamycin that has allowed for the wi

56 Recipients were injected daily with 5 mg/kg cyclosporine A and received either 10 mg/kg prednisolone

57 Alisporivir (Debio-025) is an analogue of cyclosporine A and represents the prototype of a new cla

58 The immunosuppressive natural products cyclosporine A and sanglifehrin A inhibit the enzymatic

59 f the most commonly used immunosuppressants, cyclosporine A and tacrolimus (FK506), inhibit the activ

60 Cyclosporine A and tacrolimus significantly reduced IFNg

61 n was strongly potentiated by combination of cyclosporine A and UVA treatment.

62 -dependent migration (including SP600125 and cyclosporine A) and differentiation (cyclosporine A only

63 Calcineurin inhibitors (FK506 and cyclosporine A) and the cathepsin L inhibitor E64 all in

64 Cyclophilin inhibitors, cyclosporine A, and alisporivir and NS5A inhibitor BMS-7

65 ross a class I MHC disparity with 12 days of cyclosporine A, and two across a class I MHC disparity w

66 ochondria and that such an effect of CypD is cyclosporine A- and Bcl2-dependent.

67 rapies using calcineurin inhibitors, such as cyclosporine A, are associated with a higher incidence o

68 e agents, azathioprine, 6-mercaptopurine and cyclosporine A, are compatible with pregnancy.

69 wis XX to DA XY allografts were treated with cyclosporine A at 10 mg/kg/day.

70 iliximab (n=5), calcineurin inhibitor (CNI) (cyclosporine A)/basiliximab (n=4) or CNI (tacrolimus)-ba

71 vulnerability to mPT and in higher levels of cyclosporine A being required to inhibit mPTP opening.

72 re proline-containing peptide substrates and cyclosporine A bind and that are vital for the enzymatic

73 bunit ring and unhooks it from cyclophilin D/cyclosporine A binding sites in the ATP synthase F1, pro

74 N-acetyl-L-cysteine and cyclosporine A, blocked ethanol and acetaldehyde-induced

75 was rescued upon MG132 treatment as well as cyclosporine A, but not by FK506 or bile acids, suggesti

76 leukin-8, and inhibited by dexamethasone and cyclosporine A, consistent with a role as a proinflammat

77 omplex systems, including the cyclic peptide cyclosporine A, constrained peptide systems, and heteroc

78 for 10 or 100 days or immunosuppressed with cyclosporine A continuously for 50 days and then withdra

79 In contrast, we found that cyclosporine A could inhibit the AA-induced loss of Delt

80 L without a calcineurin inhibitor (33%), SRL+cyclosporine A (CsA) (33%), and SRL+tacrolimus (TAC) (34

81 ipients (RTX) receiving tacrolimus (n=34) or cyclosporine A (CsA) (n=24) or an mTORi (n=26).

82 Group C received cyclosporine A (CsA) (Neoral, Novartis, Basel, Switzerla

83 monly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluoromethol

84 antly, a pharmacological inhibition of CN by cyclosporine A (CsA) ameliorated the alpha-syn-induced l

85 ses for CypA independence using Debio-025, a cyclosporine A (CsA) analog that disrupts CypA-capsid in

86 C3 and that received immunosuppression with cyclosporine A (CsA) and a predegenerated PNG (termed I-

87 ated in DHHC5-deficient hearts, inhibited by cyclosporine A (CsA) and adenosine, promoted by staurosp

88 We found that both cyclosporine A (CsA) and ascomycin inhibited removal of

89 whereas inhibitors of immunophilins, such as cyclosporine A (CsA) and FK506, inhibited CrkII, but not

90 ions, the inhibitory effects of TPR ligands, cyclosporine A (CsA) and FK506, on AR activity were not

91 The immunosuppressive drug cyclosporine A (CsA) and its nonimmunosuppressive analog

92 til (MMF) are considered more efficient than cyclosporine A (CsA) and MMF, but recent studies have ch

93 f two commonly used immunosuppressive drugs, cyclosporine A (CsA) and sirolimus (SRL), on the develop

94 te mofetil (MMF) or Everolimus combined with cyclosporine A (CsA) and steroids.

95 microperfusion due to the administration of cyclosporine A (CsA) and tacrolimus (Tac) can be evidenc

96 Cyclosporine A (CsA) and tacrolimus (Tac) provide effect

97 Cyclosporine A (CsA) and tacrolimus (TAC) were associate

98 of reduced nephron mass on nephrotoxicity by cyclosporine A (CsA) and/or sirolimus (SRL).

99 on of rituximab to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for newly dia

100 rapamil as the prototypic P-gp substrate and cyclosporine A (CsA) as the prototypic inhibitor.

101 etreatment with the NFAT signaling inhibitor cyclosporine A (CsA) blocked NaBT-mediated PTEN inductio

102 f an investigational therapy for severe VKC, cyclosporine A (CsA) cationic emulsion (CE), an oil-in-w

103 s are administered the calcineurin inhibitor cyclosporine A (CsA) chronically and demonstrate an incr

104 in an era of lower prednisone doses, whether cyclosporine A (CsA) contributes, whether hypothalamic-p

105 ts who received the combination of sirolimus-cyclosporine A (CsA) demonstrated AVN, compared with 1.4

106 Here we show that AS and cyclosporine A (CsA) exerted synergistic inhibitory effe

107 y, and we evaluated their ability to deliver cyclosporine A (CsA) for immunomodulatory applications.

108 Whether cyclosporine A (CsA) has beneficial effects in reperfuse

109 To evaluate the treatment with topical 0.05% cyclosporine A (CsA) in patients with subepithelial corn

110 cardiovascular/metabolic risk profile versus cyclosporine A (CsA) in the Belatacept Evaluation of Nep

111 Cyclosporine A (CsA) increases beta-catenin messenger RN

112 It has been suggested that cyclosporine A (CsA) induces gingival enlargement by pro

113 dro-N6-propyl-2,6-benzothiazole-diamine) and cyclosporine A (CSA) inhibited increases in ion conducta

114 Cyclosporine A (CsA) inhibits HCV replication and CsA de

115 Cyclosporine A (CsA) is a well-known immunosuppressive a

116 Cyclosporine A (CsA) is an immunosuppressive drug which

117 Cyclosporine A (CSA) is considered a "gold standard" the

118 Cyclosporine A (CsA) is used for the treatment of psoria

119 The narrow therapeutic window of cyclosporine A (CsA) means its use is controlled by phar

120 ds of patients initiated on monotherapy with cyclosporine A (CsA) microemulsion require addition of s

121 mic or pharmacological postconditioning with cyclosporine A (CsA) might protect the kidney from letha

122 in the progression of fibrosis in a chronic cyclosporine A (CsA) nephrotoxicity animal model.

123 correlates with the variation in response to cyclosporine A (CsA) noted in some clinical trials.

124 tudy evaluated whether sirolimus (SRL), with cyclosporine A (CsA) or alone, affects TA, and examined

125 Patients with acute GvHD are treated with cyclosporine A (CsA) or tacrolimus (FK506), which not on

126 n is inhibited by the immunosuppressant drug cyclosporine A (CsA) or tacrolimus (FK506).

127 s of 3-8 or 6-12 ng/mL plus reduced-exposure cyclosporine A (CsA) or to mycophenolic acid (MPA) 1.44

128 rapy combined with the calcineurin inhibitor cyclosporine A (CsA) prolonged median primary graft surv

129 ng a 7-day alphabeta- T-cell receptor (TCR)/ cyclosporine A (CsA) protocol.

130 The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ br

131 pressive action of the calcineurin inhibitor cyclosporine A (CsA) stems from the inhibition of nuclea

132 alcineurin inhibitors tacrolimus (FK506) and cyclosporine A (CSA) to enhance the activity of PHMB, am

133 after renal transplantation) conversion from cyclosporine A (CsA) to everolimus versus continued CsA

134 ty of rapamycin or the calcineurin inhibitor cyclosporine A (CSA) to promote chimerism in a murine ha

135 warm ischemia), and rats subjected to acute cyclosporine A (CSA) toxicity (50 mg/kg for 2 d intraper

136 the RNA-induced silencing complex (RISC) of cyclosporine A (CsA) treated and control human proximal

137 nts randomized (2:1) to sirolimus (n=314) or cyclosporine A (CsA) treatment (n=161).

138 veral time points: (a) SRL (CNI-free) versus cyclosporine A (CsA) treatment de novo, (b) CsA+SRL vers

139 Calcineurin inhibitors such as cyclosporine A (CsA) were shown to be effective in the t

140 ive strategies combining tacrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) an

141 After the introduction of cyclosporine A (CsA), 2-year graft survival of transplan

142 Cyclosporine A (CsA), a mitochondrial permeability trans

143 The PLGA-GA NS loaded with cyclosporine A (CsA), a model peptide, upon peroral dosi

144 Intraperitoneal injection of cyclosporine A (CsA), a pharmacological inhibitor of the

145 ression with mycophenolate mofetil (MMF) and cyclosporine A (CsA), achieved stable engraftment of dog

146 terestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to preve

147 treated with immunosuppressant drugs such as cyclosporine A (CsA), an inhibitor of calcineurin phosph

148 more than that of M6G (80.31 +/- 21.75 muM); Cyclosporine A (CsA), an inhibitor of OATP2B1, can inhib

149 were allocated to EVL plus reduced-exposure cyclosporine A (CsA), and 20 to standard dose CsA.

150 kin-2 receptor antagonists, tacrolimus (FK), cyclosporine A (CSA), and mycophenolate mofetil/sodium (

151 splant recipients treated with prednisolone, cyclosporine A (CsA), and mycophenolate sodium (MPS) for

152 ly treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and prednisone (pred).

153 free protocol was compared with a sirolimus, cyclosporine A (CsA), and prednisone-based immunosuppres

154 re swine can be induced by a short course of cyclosporine A (CsA), and that this stable tolerance is

155 f timing and duration of cardiac exposure to cyclosporine A (CsA), another putative mitochondrial pro

156 ugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), are often used together after HSCT

157 Combining Treg cells with cyclosporine A (CSA), but not rapamycin (RAPA) or mycoph

158 y side effect of the immunosuppressive drug, cyclosporine A (CsA), can be a major issue in transplant

159 on, we tested an anti-inflammatory compound, cyclosporine A (CsA), for its ability to block JCV infec

160 of AM19 and AM1c9, secondary metabolites of cyclosporine A (CsA), have been associated with nephroto

161 , following treatment with the PPI inhibitor cyclosporine A (CsA), or overexpression of a dominant-ne

162 ith immunosuppressive reagents that included cyclosporine A (CSA), rapamycin (RAP), mycophenylate mof

163 atients taking immunosuppressive drugs, like cyclosporine A (CsA), that inhibit calcineurin are highl

164 in mice treated with a potent SC activator, cyclosporine A (CSA), which inhibits the phosphatase cal

165 oxidase 2 (Nox2) plays an important role in cyclosporine A (CsA)-induced chronic hypoxia.

166 s of fibrosis-related IL-6-type cytokines in cyclosporine A (CsA)-induced gingival overgrowth (GO).

167 In this study, we examined the effects of cyclosporine A (CsA)-induced immune suppression during e

168 mavirus 1 (MmuPV1) infection caused cSCCs in cyclosporine A (CsA)-treated mice, even in the absence o

169 This study determined whether cyclosporine A (CsA)-treated renal allograft recipients

170 orally with STN alone or in combination with cyclosporine A (CsA).

171 nd are targets of the immunosuppressive drug cyclosporine A (CsA).

172 s, thymoglobulin, mycophenolate mofetil, and cyclosporine A (CsA).

173 cans without and with ABCB1 inhibition using cyclosporine A (CsA).

174 ith a 21-day course of the immunosuppressant cyclosporine A (CsA).

175 s well as incubation with the CypA inhibitor cyclosporine A (CsA).

176 st as well or better than the Pgp modulator, cyclosporine A (CSA).

177 )/mycophenolate sodium+tacrolimus (TAC), MMF+cyclosporine A (CsA); mammalian target of rapamycin inhi

178 Recipients were immunosuppressed either with cyclosporine A (CsA, 1.5 mg/kg/day subcutaneously) or wi

179 nd during infusion (6, 12, or 24 mg/kg/h) of cyclosporine A (CsA, a P-glycoprotein [P-gp] inhibitor).

180 e absence and presence of the P-gp inhibitor cyclosporine-A (CsA).

181 y higher than that of the standard inhibitor cyclosporine-A (CsA).

182 pening during the preconditioning phase with cyclosporine-A (CsA, 0.2 micromol/L) or sanglifehrin-A (

183 tide) and a model hydrophobic macromolecule (Cyclosporine A, CsA), herein we provide a mechanistic un

184 Tacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2

185 reviously shown that a 12-day treatment with cyclosporine A (CyA) facilitates induction of tolerance

186 from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regar

187 Case 1 and 2 were treated with Cyclosporine A (CyA), case 3 was treated with Duplimab w

188 to cyclosporine A monotherapy, CMPD 167 with cyclosporine A delayed alloantibody production, suppress

189 tion in the fundus vessels (P < 0.01), while cyclosporine A did not.

190 A cyclophilin D inhibitor, cyclosporine A, disrupts the CypD-Bcl2 interaction.

191 rkat cells or treatment of Jurkat cells with cyclosporine A eliminated the Vif-sensitive inhibition a

192 (also called niacinamide), minocycline, and cyclosporine A exhibited a uniform protective effect.

193 degrees C) or by treatment with substrates (cyclosporine A, FK506), modulators (tariquidar), or smal

194 Seven received cyclosporine A for 28 days and 14 received rapamycin.

195 Rats received reduced dose cyclosporine A for 28 or 56 days to allow chronic reject

196 findings may explain why patients receiving cyclosporine A for immunosuppressive therapy display exc

197 mus, KT recipients aged <=44 years receiving cyclosporine A had a higher risk of graft loss (adjusted

198 Combined administration of BJ486K and cyclosporine A had a synergistic effect in inhibition of

199 For example, use of the Cn inhibitor cyclosporine A has been shown to delay muscle regenerati

200 ochondrial permeability transition inhibitor cyclosporine A, has a requirement for mitochondrial Ca(2

201 5% CI, 1.2-3.98), and immunosuppression with cyclosporine A (HR, 1.93; 95% CI, 1.14-3.3).

202 Protocol I showed, the VBP-allo with cyclosporine A immunosuppression was electrophysiologica

203 regeneration and recruitment are impeded by cyclosporine A immunosuppression, and (4) donor GFP-posi

204 no reconstruction, VBP-allo with and without cyclosporine A immunosuppression, VBP autotransplantatio

205 e alloimmune response, which was reversed by cyclosporine A in a dose-dependent fashion.

206 Partial blocking of AIF release by cyclosporine A in OmpU-treated cells further suggests th

207 ucted from June 22, 2010, to March 13, 2013 (Cyclosporine A in Out-of-Hospital Cardiac Arrest Resusci

208 In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction

209 Immunosuppression for 12 weeks using cyclosporine A in such woodchucks resulted in transient

210 s also enhanced viral resistance to the drug cyclosporine A, indicating a reduced dependence of the c

211 Nifedipine- and cyclosporine A-induced gingival overgrowth tissues simil

212 Cyclosporine A-induced nephrotoxicity is multifactorial

213 he immunosuppressants tacrolimus (FK506) and cyclosporine A inhibit calcineurin and have potent antif

214 phosphorylation through a calcium-dependent, cyclosporine A-inhibitable pathway.

215 this occurs independently of cyclophilin D (cyclosporine A insensitive) rather it is through decreas

216 tion were observed both in mice treated with cyclosporine, a known stimulator of the HCM response, an

217 or PLCgamma2 or inhibiting calcineurin with cyclosporine A leads to increased expression of PD-1 lig

218 Calcineurin blockade by cyclosporine A led to a failure of CD8 but not CD4 toler

219 The mean doses of cyclosporine A (mg/kg/day) were recorded.

220 ) and ACI donors (group 5) were treated with cyclosporine A monotherapy (16 mg/kg/day, tapered to 2 m

221 Cyclosporine A monotherapy prevented acute rejection of

222 raft transplants across an MHC barrier under cyclosporine A monotherapy protocol.

223 In contrast, relative to cyclosporine A monotherapy, CMPD 167 with cyclosporine A

224 Allografts in group 3 (n=6) received tapered cyclosporine A monotherapy.

225 maintenance immunosuppression consisting of cyclosporine A, mycophenolate mofetil, and steroids.

226 ependent of immunosuppressive therapy (using cyclosporine A, mycophenolate mofetil, or azathioprine a

227 =27), were compared to no treatment (n=4) or cyclosporine A (n=6).

228 immunosuppression with cyclosporine A (with cyclosporine A, n=6; no cyclosporine A, n=7).

229 cyclosporine A (with cyclosporine A, n=6; no cyclosporine A, n=7).

230 Combined treatment with cyclosporine A, OA further prolonged the islet allograft

231 Medication with phenytoin, nifedipine, and cyclosporine-A often causes gingival overgrowth.

232 125 and cyclosporine A) and differentiation (cyclosporine A only) of osteoclast precursors.

233 ural Terminology codes and prescriptions for cyclosporine A ophthalmic emulsion were used to identify

234 ell treatment with the calcineurin inhibitor cyclosporine A or a NFAT-specific inhibitor led to a sha

235 aling pathway in lymphoma cells, either with cyclosporine A or anti-CD1d blocking antibody, prolonged

236 hat short term (4-6 h) treatment with 15 muM cyclosporine A or FK506 rescues the pre-formed immature

237 eliorated in T4C3 cells by pretreatment with cyclosporine A or FK506, implicating the calcium-depende

238 ation in its catalytic site, antagonism with cyclosporine A or FK506, or intracellular perfusion with

239 264)K variant was rescued by the addition of cyclosporine A or infection of a cyclophilin A-deficient

240 indicated that inhibition of calcineurin by cyclosporine A or knockdown of NFATc4 using small interf

241 si(m), and were protected from cell death by cyclosporine A or ppif ablation, implicating the mitocho

242 In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent in

243 three specific calcineurin inhibitors FK506, cyclosporine A, or calcineurin inhibitory peptide preven

244 Ca(2+) signaling or calcineurin with BAPTA, cyclosporine A, or FK506 prevented activation of NF-kapp

245 c acid, the calcineurin inhibitors FK506 and cyclosporine A, or use of acinar cells from calcineurin

246 pulses of cyclophosphamide, vincristine, or cyclosporine A; or salvage splenectomy are considered.

247 p treatment with dexamethasone (P < 0.01) or cyclosporine A (P < 0.01) significantly lowered MS adhes

248 ecedented strategy for preparing polylactide-cyclosporine A (PLA-CsA) NPs (termed CsA-NPs) through Cs

249 tch1+/- mice with immunosuppressive doses of cyclosporine A plus prednisolone for 4-1/2 mo increased

250 nts spanned four immunosuppressive eras: pre-cyclosporine A (pre-CsA) era (16%), CsA era (23%), tacro

251 In contrast, reduction of p53 levels or cyclosporine A pretreatment of mice prevents this comple

252 ading to cell death, which was attenuated by cyclosporine A pretreatment.

253 tructive jaundice, prostaglandin inhibitors, cyclosporine A, radiocontrast dyes and volatile anesthet

254 After brain injury, cyclosporine A reduces damage but is ineffective followi

255 with chaperone Hsp70, and the treatment with cyclosporine A reduces the association of mutant P-gp, t

256 Immunosuppression with high doses of Cyclosporine A, required for MSC survival, was provided

257 ion with costimulation blockade and low-dose cyclosporine A resulted in a complete deletion of periph

258 ith phosphatase inhibitors (okadaic acid and cyclosporine A) resulted in a modest inhibition of the T

259 toxicity equivalents of model P-gp inhibitor cyclosporine A) revealed high inhibitory potential of po

260 tochondrial Ca(2+) influx, by mPTP inhibitor cyclosporine A, sanglifehrin, and in cyclophilin D knock

261 Cyclosporine A selectively ameliorated the Anesthesia/Su

262 ha treated mice underwent calcium-dependent, cyclosporine A-sensitive swelling, which was prevented b

263 ells markedly induced COX-2 expression via a cyclosporine A-sensitive, calcineurin/NFAT-dependent pat

264 gamma-inducing effect of NcAg was blocked by cyclosporine, a specific ligand for CyP, in a dose-depen

265 Cyclosporine A stabilizes Ets-2 mRNA and protein when th

266 eta-turns of the orally bioavailable peptide cyclosporine A, suggests that the introduction of bioact

267 otrexate along with a calcineurin inhibitor (cyclosporine A, tacrolimus) for GVHD prophylaxis.

268 currently available immunosuppressive agents cyclosporine A, tacrolimus, and rapamycin have potent an

269 ation with either T-cell depleted marrow and cyclosporine A (TCD arm; n=201) or methotrexate and cycl

270 Upon introducing the nephrotoxin, Cyclosporine A, the epithelial barrier is disrupted in a

271 enal transplantation with a 12-day course of cyclosporine A to induce long-term tolerance.

272 It synergizes with cyclosporine A to inhibit HCV infection.

273 wever, we demonstrate that a brief course of cyclosporine A to rat renal allograft recipients promote

274 Administration of cyclosporine-A to enhance graft survival demonstrated th

275 rtrophy group (n = 5), and aortic-banded and cyclosporine A- treated cardiomyopathy group (n = 5).

276 CMV reactivation occurred earlier in cyclosporine A-treated animals compared with those recei

277 Cyclosporine A-treated animals that were given antibioti

278 Cyclosporine A-treated mice showed no signs of chronic r

279 We previously demonstrated that cyclosporine A treatment during resuscitation can signif

280 keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD pat

281 Cyclosporine A treatment reduced renal expression and se

282 We hypothesized that cyclosporine A treatment would attenuate myocardial and

283 idized to total glutathione ratio induced by cyclosporine A treatment.

284 late of diabetes development; tacrolimus and cyclosporine A treatments were associated with increased

285 kidneys long-term after 12 days of high-dose cyclosporine A, uniformly accepted donor-major histocomp

286 er patients, in women, in patients receiving cyclosporine A versus tacrolimus, and in patients with b

287 Cyclosporine A was used to enhance levels of the PET rad

288 The mitochondrial membrane stabilizer, cyclosporine A, was also able to protect these cells fro

289 yl-Val-Ala-Asp-(OMe) fluoromethyl ketone and cyclosporine A, we also showed that AD198-induced PLS3 p

290 ender, cardiovascular disease before LT, and cyclosporine A were associated with the risk of long-ter

291 HLA mismatches and cyclosporine A were independently associated with increa

292 The calcineurin phosphatase inhibitor cyclosporine A, which blocks KC terminal differentiation

293 This was mitigated by cyclosporine A, which inhibits opening of the mitochondr

294 T-cell IFN-gamma production were ablated by cyclosporine A, which inhibits signaling through the T-c

295 Higher concentrations of cyclosporine A, which interacts with cyclophilin D to de

296 2 expression in HGFs, whereas treatment with cyclosporine-A, which inhibited CD147 expression, reduce

297 -principle, the known binding interaction of Cyclosporine A with cyclophilin A protein in a yeast cel

298 sporivir, a nonimmunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition proper

299 ation with or without immunosuppression with cyclosporine A (with cyclosporine A, n=6; no cyclosporin

300 Cyclosporine A, with or without concurrent corticosteroi